Exelixis Inc
Change company Symbol lookup
Select an option...
EXEL Exelixis Inc
AZZ AZZ Inc
CRM Salesforce Inc
IVR-C Invesco Mortgage Capital Inc
MSM MSC Industrial Direct Co Inc
BLUE bluebird bio Inc
ENSV Enservco Corp
ULIHF United Laboratories International Holdings Ltd
ABOIF Aboitiz Equity Ventures Inc
VYNE Vyne Therapeutics Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Postmarket

Last Trade
Delayed
$22.30
0.03 (0.13%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$22.27
Day's Change
0.70 (3.25%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
22.35
Day's Low
21.30
Volume
(Below Average)
Volume:
2,885,907

10-day average volume:
3,439,024
2,885,907

Company Profile

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Valuation Ratios

Price/Earnings (TTM)
23.38x
Price/Sales (TTM)
4.55x
Price/Book (MRQ)
3.01x
Price/Cash Flow (TTM)
22.11x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

June 2022
Current Month
12.0M
Previous Month
10.9M
Percent of Float
3.82%
Days to Cover
5.1545 Days

Share Information

EXEL is in a share class of common stock
Float
314.4M
Shares Outstanding
320.7M
Institutions Holding Shares
494
85.77%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

No cash flow information available.

Company Officers

  • Stelios B. Papadopoulos
  • Michael M. MorrisseyCEO
  • Christopher J. SennerCFO
  • Peter LambExec.VP
  • Jeffrey J. HessekielExec.VP

Address

Insider Trading

During the most recent quarter, 339K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.